BioCentury | Nov 13, 2018
Distillery Therapeutics

Cancer

...INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could...
...in Phase I testing for MM. TARGET/MARKER/PATHWAY: B cell lymphoma 2 (BCL-2; BCL2); phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1; NOXA...
...Sloan Kettering Cancer Center B cell lymphoma 2 (BCL-2) (BCL2) Myeloid leukemia cell differentiation protein (MCL1) Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) (NOXA) B...
BioCentury | Jul 14, 2017
Clinical News

Noxxon starts Phase I/II of olaptesed pegol, Keytruda combo in cancer

Noxxon Pharma N.V. (Euronext:ALNOX) began a 2-part Phase I/II trial to evaluate olaptesed pegol (NOX-A12) plus Keytruda pembrolizumab in about 10 patients with metastatic colorectal cancer and 10 patients with metastatic pancreatic cancer. Patients will...
BioCentury | Jun 23, 2016
Targets & Mechanisms

Hide and seek

Duke University researchers and their collaborators have identified the mechanism by which breast cancer cells hide in bone marrow to evade chemotherapy, and developed a two-part strategy for flushing them out. The mechanism falls neatly...
BioCentury | Sep 29, 2014
Clinical News

Olaptesed pegol regulatory update

FDA granted Orphan Drug designation to olaptesed pegol from Noxxon to treat glioblastoma in conjunction with radiotherapy. The product is in Phase IIa testing to treat multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) and...
BioCentury | Jul 28, 2014
Clinical News

Olaptesed pegol: Additional Phase IIa data

Data from 20 evaluable patients with relapsed CLL in an open-label, dose-escalation, European Phase IIa trial showed that olaptesed pegol in combination with bendamustine and rituximab led to an ORR of 85%, including 4 complete...
BioCentury | Jul 28, 2014
Clinical News

Olaptesed pegol: Additional Phase IIa data

Data from 20 evaluable patients with relapsed MM in an open-label, dose-escalation, European Phase IIa trial showed that olaptesed pegol in combination with Velcade bortezomib and dexamethasone led to an ORR of 70%, including 6...
BioCentury | Jan 13, 2014
Clinical News

Olaptesed pegol: Interim Phase IIa data

Interim data from a pilot group of 9 evaluable patients with relapsed MM in an open-label, dose-escalation, European Phase IIa trial showed that 1, 2 and 4 mg/kg NOX-A12 in combination with Velcade bortezomib and...
BioCentury | Jan 13, 2014
Clinical News

Olaptesed pegol: Interim Phase IIa data

Interim data from a pilot group of 9 evaluable patients with relapsed CLL in an open-label, dose-escalation, European Phase IIa trial showed that 1, 2 and 4 mg/kg NOX-A12 in combination with bendamustine and rituximab...
BioCentury | Apr 18, 2013
Tools & Techniques

Expanding the aptamer alphabet

Researchers at the RIKEN Center for Life Science Technologies and TagCyx Biotechnologies have used an expanded genetic alphabet containing unnatural nucleotides to generate DNA aptamers that have 100-fold higher binding affinity for a target protein...
BioCentury | Oct 8, 2012
Clinical News

NOX-A12: Phase IIa started

Noxxon began an open-label, dose-escalation, European Phase IIa trial to evaluate 1, 2 and 4 mg/kg NOX-A12 in combination with Velcade bortezomib and dexamethasone in 8 cycles of 21 days in about 28 previously treated...
Items per page:
1 - 10 of 24